

Belimumab in Autoimmune Hepatitis

NCT06381453

Status	RECRUITING
Phase	Phase 2
Sponsor	University Health Network, Toronto
Enrollment	48 participants

Key Eligibility Criteria

Inclusion (10)

- Ability to provide written informed consent
- Established clinical diagnosis of autoimmune hepatitis for at least 6 months
- Participant and clinician consent to follow AIH study therapy guidance for the duration of the open label clinical trial.
- Group A:
 - ALT $\geq 1.5 \times$ ULN in the absence of clinical evidence or concern for alternative etiology, and assessed by the investigator as related to active AIH using standard of care evaluation.

... and 5 more (see full listing online)

Exclusion (12)

- Primary liver disease other than AIH
- High probability of NAFLD as assessed by the investigator.
- ALT $\geq 15 \times$ ULN
- Patients positive for HBsAg or HBcAb and/or Hepatitis C RNA
- Prior use of corticosteroid ≥ 15 mg daily

... and 7 more (see full listing online)

Locations (5 total)

University of Calgary, Calgary, Alberta, Canada
G.I Research Institute, Vancouver, British Columbia, Canada
McMaster University, Hamilton, Ontario, Canada

... and 2 more locations